Press Releases Latest May 02, 2024 Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting Press Releases Year None202420232022202120202019201820172016201520142013 Feb 16, 2022 Theratechnologies Presents Results From Trogarzo® IV Push Administration Study at CROI 2022 Feb 15, 2022 Theratechnologies Strengthens Global Commercial Capabilities by Launching Internal Field Force Feb 10, 2022 Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021 Dec 06, 2021 Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV Nov 26, 2021 Theratechnologies Named Recipient of the 2021 ADRIQ Innovation Award in the "Life Sciences" Category Nov 23, 2021 Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended Nov 03, 2021 Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 Oct 26, 2021 Theratechnologies Announces Reimbursement Agreement in Italy for Trogarzo® for Eligible Patients With Multi-Drug Resistant HIV-1 Oct 22, 2021 Theratechnologies Announces Publication in Frontiers in Oncology Journal Highlighting SORT1+ Technology™ for Targeting SORT1-Mediated Vasculogenic Mimicry Oct 13, 2021 Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2021 and Provides Business Update First page « Previous page ‹ … Page 6 Page 7 Page 8 Page 9 Current page 10 Page 11 Page 12 Page 13 Page 14 … Next page › Last page » Displaying 91 - 100 of 361
May 02, 2024 Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
Feb 16, 2022 Theratechnologies Presents Results From Trogarzo® IV Push Administration Study at CROI 2022
Feb 15, 2022 Theratechnologies Strengthens Global Commercial Capabilities by Launching Internal Field Force
Feb 10, 2022 Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021
Dec 06, 2021 Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV
Nov 26, 2021 Theratechnologies Named Recipient of the 2021 ADRIQ Innovation Award in the "Life Sciences" Category
Nov 23, 2021 Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended
Nov 03, 2021 Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021
Oct 26, 2021 Theratechnologies Announces Reimbursement Agreement in Italy for Trogarzo® for Eligible Patients With Multi-Drug Resistant HIV-1
Oct 22, 2021 Theratechnologies Announces Publication in Frontiers in Oncology Journal Highlighting SORT1+ Technology™ for Targeting SORT1-Mediated Vasculogenic Mimicry
Oct 13, 2021 Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2021 and Provides Business Update
